



NOVEL 2,5-DISUBSTITUTED-1H-PYRROLES WITH HIGH AFFINITY FOR THE DOPAMINE D₃ RECEPTOR: N-BENZYL MODIFICATIONS

Izzy Boyfield, Martyn C. Coldwell, Michael S. Hadley, Maureen A.M. Healy, Christopher N. Johnson.

David J. Nash, Graham J. Riley, Emma E. Scott, Stephen A. Smith and Geoffrey Stemp*


*SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue,
Harlow, Essex, CM19 5AW, UK.*

Abstract: A series of 2,5-disubstituted-1H-pyrroles (**4** - **26**) has been prepared where the conformational requirements of the N-ethyl, N-benzyl side-chain of **1** and the effect of introducing substituents into the benzyl group have been investigated. The (R)- α -methylbenzyl **6** and aminoindane **10** side-chains retained high affinity for the dopamine D₃ receptor, although neither showed the selectivity of 2-phenylazacycloheptane **2**.

© 1997, Elsevier Science Ltd. All rights reserved.

The majority of drugs currently used to control the symptoms of schizophrenia have poor side-effect profiles, which in many cases leads to low patient compliance and costly re-hospitalization. The recent classification¹⁻³ of dopamine D₂-like receptors into the D₂, D₃ and D₄ subtypes, together with receptor distribution studies, has given rise to the proposal that the extra-pyramidal side-effects associated with currently available drugs result from blockade of dopamine D₂ receptors and that selective dopamine D₃ antagonists would offer the potential for antipsychotic therapy free of such side-effects.²

In a recent publication⁴, we described the discovery of the novel 2,5-disubstituted pyrrole **1** with an N-ethyl, N-benzyl side chain as a high affinity (pK_i 9.5) ligand at the dopamine D₃ receptor. We also demonstrated that conformational restriction of this side chain to give the 2-phenylazacycloheptane **2** maintained high affinity (pK_i 8.9) at the dopamine D₃ receptor and improved selectivity over the D₂ receptor. This *Letter* describes our investigations into the effect on D₃ affinity and selectivity of alternative modes of conformational restraint of the N-ethyl, N-benzyl side chain of **1** (Table 1) and the effect of introducing substituents into the side-chain phenyl groups of **1** and **2** (Tables 2 and 3).



Novel compounds **4** - **26** were readily prepared, as described previously,⁴ from the known 2-[(5-ethylsulfonyl-2-methoxy)phenyl]-1H-pyrrole **35** either by Mannich reaction with the appropriate amine or by reaction with the Vilsmeier reagent derived from the appropriate amide, followed by *in situ* reduction with NaBH₄. All compounds were then purified by chromatography and isolated as their hydrochloride salts.

Compounds **1**, **2** and **4** - **26** were evaluated using displacement of ^{125}I -iodosulpride from human D_3 and D_2 receptors, expressed in CHO cells, and results are shown in Tables 1-3.

Table 1. Effects of Side Chain Modification on Affinities at Human Cloned D_3 and D_2 Receptors

Compound ^a	R	D_3^b	D_2^b	Selectivity
1		9.5	9.1	3
2		8.9	7.4	30
4		7.5	7.0	3
5		8.0	7.4	4
6		9.1	8.1	10
7		8.6	7.6	10
8		7.0	6.8	-
9		8.0	7.4	4
10		9.1	9.1	-
11		8.3	7.9	3


^a All new compounds gave satisfactory analytical and/or mass spectral data. ^b Affinities are pK_i values. All values represent the mean of at least 3 experiments, each within 0.3 of the mean.

Initially, cyclisation of the N-ethyl chain onto the phenyl ring of the N-benzyl to give tetrahydroisoquinoline **4** was investigated, but this mode of conformational restraint reduced both D_3 and D_2 affinity by approximately 100-fold. Cyclisation of the N-ethyl group onto the carbon α - to the pyrrole ring to give N-benzyl pyrrolidine **5** also resulted in a marked reduction in D_3 and D_2 affinity compared to **1**. However, introduction of conformational restraint into the N-benzyl side chain *via* a methyl group at the benzylic position gave the (R)- and (S)-enantiomers, **6** and **7** respectively, which proved more interesting. (R)-enantiomer **6** maintained the high affinity of **1** at the D_3 receptor and had slightly reduced D_2 affinity to give a compound with 10-fold selectivity. A similar change in selectivity was also found with the (S)-enantiomer **7**, although affinity at both D_3 and D_2

receptors was reduced compared to **6**. The improved selectivity observed with **6** and **7** prompted the synthesis of 2,5-disubstituted pyrrolidines **8** and **9**, where the benzylic methyl is cyclised onto the carbon α - to the pyrrole ring. However, both the *cis*- and *trans*-isomers, **8** and **9** respectively, showed marked reductions in D₃ affinity compared to **6** and **7**, with only the *trans*-isomer **9** retaining respectable D₃ affinity and 4-fold selectivity over D₂. Finally in this series, the effect of cyclisation of the benzylic methyl to the *ortho*-position of the phenyl ring to give 1-aminoindane **10** and 1-aminotetralin **11** was investigated. The results with these two compounds highlighted the sensitivity of D₃ and D₂ affinity to subtle changes in the orientation of the phenyl ring compared to the basic nitrogen. Aminoindane **10** retained the high D₃ affinity associated with **1**, but was non-selective; on the other hand, aminotetralin **11** showed reduced D₃ and D₂ affinity compared to **1**.

These studies on conformational restriction of the high affinity N-ethyl, N-benzyl side chain of **1** demonstrated that some modes of constraint, such as introduction of a benzylic methyl group **6** or cyclisation to aminoindane **10**, could be tolerated. They also confirmed the 2-phenylazacycloheptane **2** as the optimum side chain in this series in terms of D₃ affinity and selectivity over the D₂ receptor. We therefore turned our attention to investigating the influence on D₃ affinity of substituents in the phenyl ring of both the N-ethyl, N-benzyl and 2-phenylazacycloheptane side chains (Tables 2 and 3).

Table 2. Effects of Benzyl Substitution on Affinities at Human Cloned D₃ and D₂ Receptors




Compound ^a	R	D ₃ ^b	D ₂ ^b	Selectivity
1	H	9.5	9.1	3
12	2-Cl	8.2	7.7	3
13	2-Me	8.5	8.2	2
14	2-OMe	8.0	7.8	-
15	3-Cl	8.6	8.0	4
16	3-Me	8.8	8.1	5
17	3-OMe	8.1	7.1	10
18	4-Cl	9.4	9.0	3
19	4-Me	9.7	9.4	2
20	4-OMe	9.6	8.7	8
21	3,4-diOMe	7.9	7.5	3
22	3,4-methylenedioxy	9.2	8.5	5

Footnotes: See Table 1.

In general, substitution at the 2- or 3- positions resulted in a reduction in D₃ affinity compared to **1**. However, a 3-OMe substituent, as in **17**, produced a larger reduction in D₂ affinity to give a compound with 10-fold selectivity. At the 4-position, both electron-withdrawing and donating groups were tolerated, with a 4-OMe substituent **20** giving a slight enhancement in selectivity. These results prompted the synthesis of the 3,4-diOMe analogue **21**, which was significantly lower in affinity than **20**. However, cyclisation of the methoxy groups of **21** to a 3,4-methylenedioxy group **22** restored D₃ affinity, suggesting that in **21** the methoxy groups have an

adverse conformational effect on one another. Following these results, a limited range of substituents was investigated in the phenylazacycloheptane series (Table 3). The results broadly paralleled those in the N-ethyl, N-benzyl series with the 4-OMe and 4-Me analogues **25** and **26** having similar D₃ affinities and selectivities to **2**.

Table 3. Effects of Phenyl Substitution on Affinities at Human Cloned D₃ and D₂ Receptors



Compound ^a	R	D ₃ ^b	D ₂ ^b	Selectivity
2	H	8.9	7.4	30
23	2-Me	7.0	5.9	10
24	3-OMe	7.3	6.1	15
25	4-OMe	8.8	7.6	15
26	4-Me	9.1	7.6	30

Footnotes: See Table 1.

In conclusion, investigation of alternative modes of conformational restriction of the high affinity N-ethyl, N-benzyl side-chain of **1** resulted in (R)- α -methylbenzyl **6** and aminoindane **10** which retained high D₃ affinity, although neither showed the selectivity of 2-phenylazacycloheptane **2**. Comparison of substituent effects between the N-ethyl, N-benzyl and 2-phenylazacycloheptane series indicates that the phenyl rings of each series probably interact with the same region of the D₃ receptor. This suggests that the enhanced selectivity of **2** may arise from an unfavourable steric interaction of the azacycloheptane ring with the D₂ receptor, although the possibility cannot be ruled out that the selectivity of **2** reflects a more advantageous orientation of the 2-phenyl group for interaction with the D₃ receptor.

References and Notes

1. Grandy, D. K.; Marchionni, M. A.; Makam, H.; Stofko, R. E.; Alfano, M.; Frothingham, L.; Fischer, J. B.; Burke-Howie, K. J.; Bunzow, J. R.; Server, A. C.; Civelli, O. *Proc. Nat. Acad. Sci.* **1989**, *86*, 9762-9766.
2. Sokoloff, P.; Giros, B.; Martres, M.-P.; Bouthenet, M.-L.; Schwartz, J.-C. *Nature*. **1990**, *347*, 146-151.
3. Van Tol, H. H. M.; Bunzow, J. R.; Guan, H.-C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O. *Nature*. **1991**, *350*, 610-614.
4. Bolton, D.; Boyfield, I.; Coldwell, M. C.; Hadley, M. S.; Healy, M. A.; Johnson, C. N.; Markwell, R. E.; Nash, D. J.; Riley, G. J.; Stemp, G.; Wadsworth, H. *BioMed. Chem. Letts.* **1996**, *6*, 1233-1236.
5. van Wijngaarden, I.; Kruse, C. G.; van Hes, R.; van der Heyden, J. A. M.; Tulp, M. T. M. *J. Med. Chem.* **1987**, *30*, 2099-2104.
6. ¹H NMR spectra were recorded at 250 MHz in CDCl₃ as solvent. Compound **6**, mpt 143-145 °C; ¹H: δ 1.20 (t, 3H), 1.25 (t, 3H), 1.90 (m, 3H), 2.65-3.30 (m, 4H), 3.95-4.50 (m, 2H), 4.20 (s, 3H), 4.60-4.80 (m, 1H), 6.25 (m, 1H), 6.60 (m, 1H), 7.10 (d, 1H), 7.40-7.55 (m, 3H), 7.60-7.80 (m, 3H), 8.15 (d, 1H), 11.80 (br m, 1H), 12.10 (br s, 1H). Compound **10**, mpt 151-155 °C; ¹H (mixture of protomers): δ 1.30 (m, 6H), 2.30-2.65 (m, 2H), 2.70-3.20 (m, 6H), 4.10-4.55 (m, 2H), 4.20 (s, 3H), 4.95 and 5.05 (2 x t, 1H), 6.30 and 6.35 (2 x m, 1H), 6.55 (m, 1H), 7.10 (d, 1H), 7.30 (m, 3H), 7.70 and 7.85 (2 x dd, 1H), 8.15 (m, 1H), 11.70 and 11.95 (2 x br s, 1H), 12.30 and 12.55 (2 x br s, 1H).